Pancreatic Cancer Research

Clinical trialPhase 2 / Phase 3Unknown

Metronomic Chemotherapy With Capecitabine for Pancreatic Cancer

A Multi-center, II Phase，Randomized Controlled Clinical Study of Capecitabine Metronomic Chemotherapy After Gemcitabine Plus Capecitabine Standard Adjuvant Therapy for Stage II/III Pancreatic Cancer

NCT03959150↗ ClinicalTrials.gov, retrieved 4 November 2026

Outcome
Outcome unknown
Phase
Phase 2 / Phase 3
Status
Unknown
Study type
Interventional
Start
5 January 2020
Expected end
30 June 2023
Enrollment
231 participants
Sites
1
Primary outcomes
One year disease-free survival
Sponsor
Other
Results posted
No
Last update
30 April 2021

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Papers 10